PSILORIS

Educational resource only. Not medical advice. Psilocybin remains illegal or restricted in many jurisdictions.

Full safety notice
← All conditions
Promising evidence

Major Depressive Disorder & Treatment-Resistant Depression: psilocybin research evidence

Multiple modern trials and several meta-analyses show rapid and clinically meaningful antidepressant effects from psilocybin-assisted therapy in major depression and treatment-resistant depression. Durability, blinding limits, harms reporting, and supervised-setting requirements remain active research questions.

Last reviewed: 2026-07-26

Evidence narrative

Evidence section. Peer-reviewed findings and evidence-graded interpretation only.

Why this condition is marked promising

Depression — particularly treatment-resistant depression (TRD) — is the most mature clinical indication for psilocybin-assisted therapy. Open-label feasibility work was followed by randomised trials showing large effect sizes versus waitlist, low-dose, or niacin controls, with some cohorts retaining benefit at longer follow-up. Head-to-head and multicenter data, plus multiple systematic reviews, strengthen the case while also clarifying limits.

What the evidence currently supports

  • Rapid reductions in depressive symptom scores after one or two supervised dosing sessions with psychological support (including Davis 2021 MDD; Goodwin 2022 TRD; Raison 2023 MDD).
  • Signals of durability lasting weeks to months in subsets of participants (including 12-month follow-up after the Johns Hopkins MDD programme).
  • Meta-analytic estimates of moderate average benefit versus controls, with dose-response analyses often favouring ~25 mg synthetic doses for MADRS change.
  • Neuroimaging correlates involving shifts in rigid self-referential network dynamics, often discussed in relation to the default mode network.
  • A head-to-head signal versus escitalopram that did not meet the primary endpoint for superiority, while secondary outcomes generally favoured psilocybin.
  • Larger Phase 2b programmes such as EPIsoDE (n=144 TRD) show clinically meaningful symptom change can occur alongside inconclusive primary endpoints — a reminder that effect sizes and trial design both matter.

Important limitations

  • Sample sizes remain modest relative to conventional antidepressant programmes; effects often attenuate in larger or more tightly controlled trials.
  • Blinding is difficult; expectancy effects and financial conflicts of interest are genuine methodological concerns highlighted in recent meta-analyses.
  • Not everyone responds. Serious adverse trajectories — including worsened suicidal ideation and prolonged somatic sequelae — are documented even in supervised Phase 2 settings.
  • Concurrent serotonergic antidepressants may attenuate subjective effects; medication washout protocols in trials are specialised and must be clinician-managed.

Practical reading for clinicians and patients

Treat current findings as strong early clinical evidence, not as a guarantee of cure. PSILORIS categorises depression as promising because replicated controlled signals and synthesised RCT evidence exist, while still requiring careful consent, screening, and integration support.

Citations

[1] randomized controlled trial · 2026

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

Mertens LJ, Koslowski M, Betzler F, et al. — JAMA Psychiatry

German two-centre EPIsoDE trial (n=144 TRD) tested 25 mg vs 5 mg vs nicotinamide active placebo with psychotherapy; clinically meaningful symptom reductions were observed, but the primary efficacy comparison was inconclusive/nonsignificant, and serious adverse reactions including panic/HPPD-spectrum sequelae were reported.

DOI: 10.1001/jamapsychiatry.2026.0132

[2] systematic review · 2025

Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs

Borgogna NC, Owen T, Petrovitch D, et al. — Psychopharmacology

Across nine RCTs (n≈602), psilocybin was moderately superior to controls for depression (g≈0.62), with heterogeneous effects, high risk of bias in many trials, incomplete harms reporting, and attenuation of effects in larger/better-controlled studies.

DOI: 10.1007/s00213-025-06788-w

[9] randomized controlled trial · 2022

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Goodwin GM, Aaronson ST, Alvarez O, et al. — New England Journal of Medicine

A single 25 mg dose of synthetic psilocybin reduced depression severity versus a 1 mg control dose in treatment-resistant depression, with dose-related adverse events noted.

DOI: 10.1056/NEJMoa2206443

[12] randomized controlled trial · 2021

Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris R, Giribaldi B, Watts R, et al. — New England Journal of Medicine

Head-to-head comparison of two 25 mg psilocybin sessions versus escitalopram over six weeks; primary QIDS-SR-16 endpoint did not differ significantly, while several secondary outcomes favoured psilocybin without multiplicity correction.

DOI: 10.1056/NEJMoa2032994

Anecdotal reports

Browse anecdote library →
Anecdote section. Not clinical evidence. Included for context and research-question generation only.